NovoCure Reports Record Q3 2026 Revenue and Raises Full-Year Guidance
NovoCure (NVCR) reported record third-quarter net revenue of $193 million, representing a 16% year-over-year increase driven by the Optune Gio brain cancer treatment. The company achieved adjusted EBITDA positivity of $16 million, marking a significant milestone in its path toward sustained profitability as major launch infrastructure spending begins to wind down. While expansion in Japan for the Optune Lua lung cancer treatment is progressing well and expected to become the company's second-largest market, NovoCure faces headwinds in its pancreatic cancer segment. The introduction of a competing drug, diraxonrasib, has slowed prescribing growth for Optune Pax due to increased clinical burdens regarding insurance appeals and side-effect management. Based on strong commercial momentum, management raised its full-year revenue guidance to a range of $736 million to $743 million. The company expects to realize significant P&L leverage as it transitions from heavy investment into a phase of operational efficiency heading into 2027.
Tickers: $NVCR
Topics: earnings report EBITDA market expansion oncology devices revenue growth